The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

被引:0
作者
Grit Hutter
Malte Rieken
Alessandro Pastore
Oliver Weigert
Yvonne Zimmermann
Marc Weinkauf
Wolfgang Hiddemann
Martin Dreyling
机构
[1] University Hospital Grosshadern,Department of Medicine III
[2] Helmholtz Centre Munich,Urologische Klinik
[3] Universitätsspital Basel,undefined
来源
Annals of Hematology | 2012年 / 91卷
关键词
MCL; Bortezomib; AraC; Apoptosis; Cell cycle arrest;
D O I
暂无
中图分类号
学科分类号
摘要
Single-agent bortezomib, a potent, selective, and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL). Objective response is achieved in up to 45% of the MCL patients; however, complete remission rates are low and duration of response proved to be relatively short. These limitations may be overcome by combining proteasome inhibition with conventional chemotherapy. Rational combination treatment and schedules require profound knowledge of underlying molecular mechanisms. Here we show that single-agent bortezomib treatment of MCL cell lines leads to G2/M arrest and induction of apoptosis accompanied by downregulation of EIF4E and CCND1 mRNA but upregulation of p15(INK4B) and p21 mRNA. We further present synergistic efficacy of bortezomib combined with cytarabine in MCL cell lines. Interestingly this sequence-dependent synergistic effect was seen almost exclusively in combination with AraC, indicating that pretreatment with cytarabine, followed by proteasome inhibition, may be the preferred approach.
引用
收藏
页码:847 / 856
页数:9
相关论文
共 151 条
[1]  
Ciechanover A(1994)The ubiquitin–proteasome proteolytic pathway Cell 79 13-21
[2]  
Orlowski RZ(2008)Proteasome inhibitors in cancer therapy: lessons from the first decade Clin Cancer Res 14 1649-1657
[3]  
Kuhn DJ(2004)The development of proteasome inhibitors as anticancer drugs Cancer Cells 5 417-421
[4]  
Adams J(2006)The proteasome: a novel target for anticancer therapy Clin Transl Oncol 8 313-317
[5]  
Montagut C(2003)A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609-2617
[6]  
Rovira A(2006)Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma Curr Opin Oncol 18 598-608
[7]  
Albanell J(2008)Bortezomib: a novel chemotherapeutic agent for hematologic malignancies Am J Health Syst Pharm 65 1221-1231
[8]  
Richardson PG(2009)Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma Br J Haematol 146 652-655
[9]  
Barlogie B(2009)Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial Br J Haematol 145 34-39
[10]  
Berenson J(2009)Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study Ann Oncol 20 520-525